Product NDC: | 0074-3826 |
Proprietary Name: | Depakote |
Non Proprietary Name: | Divalproex Sodium |
Active Ingredient(s): | 250 mg/1 & nbsp; Divalproex Sodium |
Administration Route(s): | ORAL |
Dosage Form(s): | TABLET, EXTENDED RELEASE |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 0074-3826 |
Labeler Name: | AbbVie Inc. |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | NDA021168 |
Marketing Category: | NDA |
Start Marketing Date: | 20000804 |
Package NDC: | 0074-3826-72 |
Package Description: | 5 BLISTER PACK in 1 CARTON (0074-3826-72) > 4 TABLET, EXTENDED RELEASE in 1 BLISTER PACK |
NDC Code | 0074-3826-72 |
Proprietary Name | Depakote |
Package Description | 5 BLISTER PACK in 1 CARTON (0074-3826-72) > 4 TABLET, EXTENDED RELEASE in 1 BLISTER PACK |
Product NDC | 0074-3826 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | Divalproex Sodium |
Dosage Form Name | TABLET, EXTENDED RELEASE |
Route Name | ORAL |
Start Marketing Date | 20000804 |
Marketing Category Name | NDA |
Labeler Name | AbbVie Inc. |
Substance Name | DIVALPROEX SODIUM |
Strength Number | 250 |
Strength Unit | mg/1 |
Pharmaceutical Classes | Anti-epileptic Agent [EPC],Decreased Central Nervous System Disorganized Electrical Activity [PE],Mood Stabilizer [EPC] |